On 2 October 2003, orphan designation (EU/3/03/162) was granted by the European Commission to Monoclonal Antibodies Therapeutics (MAT), France, for yttrium (90Y) antiferritin polyclonal antibodies for the treatment of Hodgkin lymphoma.
In January 2013, Monoclonal Antibodies Therapeutics (MAT) changed its name to Mablife.
For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.
Yttrium (90Y) antiferritin polyclonal antibodies
|Disease / condition||
Treatment of Hodgkin lymphoma
|Date of decision||
|Orphan decision number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.